AimThat clinical trial (RAINBOW) showed that a 7. 4 months overall survival benefit with the combination therapy with ramucirumab (RAM) and paclitaxel (PAC) as second-line therapy for patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma. compared with placebo (PLA) plus paclitaxel. We performed an analysis to assess the cost-effectiveness of RAM ... https://www.soiebiologique.com/